Calcort 6mg 20 tabs, Deflazacort
THIS IS A BRAND MEDICATION
Oral corticosteroid. The active substance Calcort ®, deflazacort, a glucocorticoid with antiinflammatory and immunosuppressive properties, indicated for the treatment of:
Endocrine disorders: primary or secondary adrenal insufficiency (Calcort ® treatment may be associated with hydrocortisone or cortisone, to finish mineralocorticoid meet the needs of the patient), congenital adrenal hyperplasia, nonsuppurative thyroiditis.
Rheumatic diseases: psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, acute and subacute bursitis, acute nonspecific tenosynovitis, acute gouty arthritis, post-traumatic osteoarthritis, synovitis of osteoarthritis, epicondylitis.
Collagen diseases: Lupus erythematosus, acute rheumatic carditis, polymyalgia rheumatica, polyarteritis nodosa, systemic dermatomyositis (polymyositis), temporal arteritis, Wegener's granulomatosis.
Dermatologic diseases: pemphigus, bullous dermatitis herpetiformis, erythema multiforme major (Stevens-Johnson disease), exfoliative dermatitis, mycosis fungoides, severe psoriasis, severe seborrheic dermatitis.
Allergic Diseases: Control of severe or incapacitating allergic reactions unresponsive to nonsteroidal drugs, seasonal or perennial allergic rhinitis, bronchial asthma, contact dermatitis, atopic dermatitis, serum sickness, drug hypersensitivity reactions.
Respiratory diseases: systemic sarcoidosis, Loeffler's syndrome, hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, aspiration pneumonia.
Ophthalmic Diseases: Inflammation of the cornea, diffuse posterior uveitis and choroiditis, keratitis, chorioretinitis, iritis and iridocyclitis, optic neuritis, sympathetic ophthalmia, ophthalmic zoster, allergic conjunctivitis.
Hematological diseases: idiopathic thrombocytopenic purpura, secondary thrombocytopenia, acquired hemolytic anemia (autoimmune) erythroblastopenia, congenital hypoplastic anemia (erythroid).
Neoplastic diseases: leukemia, lymphoma, multiple myeloma.
Renal disease: nephrotic syndrome.
Gastrointestinal diseases: ulcerative colitis, regional enteritis, chronic hepatitis.
Neurological diseases: multiple sclerosis exacerbation.
Due to its ability to cause less bone loss than other corticosteroids, deflazacort may be the drug of choice for people at increased risk of osteoporosis
Deflazacort or hypersensitivity to any component of the formula.
Patients receiving live virus immunizations.
Patients undergoing treatment or are treated with glucocorticoids and are subjected to unusual stress may need a higher dose before, during and after the stressful condition (see DOSAGE AND ADMINISTRATION.)
Glucocorticoids may mask signs of infection and new infections may occur during use.
Patients with viral, bacterial or fungal infections should be closely monitored active.
DOSAGE AND ADMINISTRATION:
The glucocorticoid deflazacort is a derivative of prednisolone and 6 mg of deflazacort have approximately the same anti-inflammatory potency as 5 mg of prednisone or prednisolone.The dose required is variable and should be individualized based on the disease being treated and patient response.
Adults: In acute and acute exacerbations of clinical conditions, initially recommended dose to120 mg once a day. The usual maintenance dose for most conditions is up to 18 mg once aday.
Children: Indications of glucocorticoids in children are the same as in adults, but it is important to use the lowest effective dose. The alternate day dosing may be appropriate.
Usually the dose is 0.25 to 2 mg / kg / day. It is recommended to shake the bottle before useand dilute the suspension immediately before administration with water, sugar or other drinks without carbon dioxide.
Name of medicine: Calcort
Comparable patent medicine: Calcort
Active ingredient: Deflazacort
Concentration: 6 mg
Extended-release tablets: No
Lab: Sanofi aventis de Mexico, SA de CV
Box of 20 pills
Made in: Mexico